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There are good grounds in Finland to choose medicinal
products for children as the strategic area for focussing on in
the EU. Paediatrics has a solid historical tradition in this
country. The inheritance of Arvo Ylppö, Archiatrist, the for-
mer doyen of Finnish medicine, in the development of
research and education in paediatrics and of a network of
child welfare centres, is widely recognised. Finnish paediatric
research is of a leading international standard. Owing to the
well organised uniform education system in Finland, the
country has more paediatricians per capita than any other
EU country.
The National Agency for Medicines is consequently well
equipped for dealing with the increasing challenges imposed
by the EU regulatory control in medicines as published in
2005 in the EMEA Road Map 2010. As one of its key mea-
sures, the EMEA proposes the setting up of a Network of
Excellence of all the specialised national evaluation centres.
Specialisation and sharing of work are the prerequisite for
the future high-level evaluation of quality, efficacy and safety
of medicinal products in the EU. Among the first national
drug regulatory authorities, the NAM in 2004 published its
own strategic areas of focus in the EU.
The EC regulation on medicinal products for paediatric
use will rank as an important historical turning point in the
development of paediatric care. The aim of the regulation is
to increase the research and development of medicinal prod-
ucts and pharmaceutical forms for children, and to promote
the collaboration between the drug industry and regulatory
authorities at the administrative and scientific level. The
preparation of the regulation is nearing completion, which
may be reached in June or in July. The regulatory activities
due to the new legislation will challenge the NAM during
the forthcoming Finnish Presidency at the end of this year. 
The EC regulation on medicinal products for paediatric
use includes an obligation to conduct research into these
products. During the development of the product, the phar-
maceutical company is obliged to present an investigation
plan (PIP) to the Paediatric Committee (PC), which will be
set up by the EMEA, and to apply for a separate waiver from
the requirements if it considers a paediatric use marketing
authorisation unnecessary. PIP is a prerequisite for approval
of an adult-use marketing authorisation as well.
As a result of the regulation concerning medicinal prod-
ucts for paediatric use, the number of clinical trials in chil-
dren will increase. To avoid overlapping and unnecessary tri-
als and to safeguard a faster progress in drug development,
the regulation includes a proposal for setting up a European
paediatric clinical trials network which would combine
national research networks and clinical trial centres. In Fin-
land, representatives of paediatric clinics in University Hos-
pitals and the Finnish Paediatric Society, together with the
NAM’s experts, held discussions towards establishing a
national network. The EU network for research of paediatric
drugs is expected to be in place and operating during 2007.
The National Agency for Medicines offers excellent
opportunities to leading Finnish paediatrics to influence the
EU regulatory control of these products. The NAM is
actively building up its country-wide network of experts to
carry out the evaluation responsibilities of the EMEA. Phar-
maceutical companies engaged in the development of medic-
inal products for paediatric use will benefit from collaborat-
ing with the NAM.
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Treatment of acne
The disease can have a significant
influence on an adolescent’s quality of
life and mental wellbeing – even
exceeding the influence of asthma or
epilepsy (1). The pathogenesis of the
disease is essentially explained by the
androgen hormone production in the
body, increased production of sebum
in the sebaceous glands, hypercornifi-
cation and clogging of the sebaceous
gland ducts, proliferation of Propioni-
bacteria and inflammation of the seba-
ceous gland and its environs. Heredi-
tary predisposition is a consequential
factor especially in the most severe
forms of acne. An attempt should be
made to target the treatment at as
many of the above stages as possible
(2).
Diagnosis
The diagnosis of acne is generally
uncomplicated. The occurrence of
comedones is the cornerstone of the
diagnosis. In the absence of these, the
differential diagnosis should focus on
e.g. rosacea, folliculitis and sebaceous
gland hyperplasia. In the planning of
treatment of the acne, it is recommen-
ded that the degree of severity be
determined and recorded. The simplest
method of differentiation is that of
dermatological changes: 1) comedonal
acne, 2) inflamed nodules and come-
dones, 3) pus-filled nodules in addi-
tion to the aforementioned, 4) cysts or
follicles in addition to the aforemen-
tioned. Development of residual scar-
ring deserves special attention. Milder
forms of acne may also produce scar-
ring, in which case more effective ther-
apies should be considered. Further
examination is seldom necessary. Poly-
cystic ovary disease ought to be sus-
pected in overweight women with
severe or recalcitrant acne, disorders of
the menstrual cycle, and dermatologi-
cal changes indicative of insulin resis-
tance such as acanthosis nigricans and
abundance of skin tags.
Topical treatment
The most effective topical treatment of
comedonal acne is a retinoid ointment
or gel. The available therapies in Fin-
land include tretinoin cream (0.025%
and 0.05%) and adapalene gel (0.1%).
The most common adverse effects of
topical retinoids are dryness of the
mouth and symptoms of irritability,
which are more common in our cold
climate. Slight redness and scaling are
nevertheless associated with the treat-
ment. Acclimatisation of the skin can
be accomplished by using a mild
strength of the drug at the outset, by
applying and leaving the ointment on
the skin for only a couple of hours at
first, and by having days off the treat-
ment altogether. The ointment should
nevertheless be applied to the entire
area of the acne and not only to the
individual dermatological changes.
Azelaic acid is a comedolytic agent
which also decreases the presence of
Propionibacteria. The onset of effect is
slower than that of retinoids, but it
causes less drying and irritation. The
available range consists of a 15% gel
and a 20% cream.
Benzoyl peroxide effectively
decreases the presence of Propionibac-
teria in the sebaceous gland. It also has
a keratolytic effect, i.e. it reduces the
presence of comedones. It therefore
even works well alone in milder forms
of acne. It would appear that benzoyl
peroxide is not associated with the
problem of resistance development by
Propionibacteria. The available
treatments include a 4% cream, a 5%
gel, and a washing gel which is practi-
cal over extensive areas of skin such as
on the back and chest. The treatment
often causes scaling, dryness and irrita-
tion of the skin in the beginning,
receding on continuation. It is recom-
mended that the patient be advised at
the start of the treatment about the risk
of fading in the colours of textiles. Top-
ical benzoyl peroxide is the safest treat-
ment alternative in pregnancy.
The only topical antibiotics avail-
able in Finland are clindamycin as a
1% solution and as a 1% ointment.
Topical antibiotic therapy should
always be combined with a comedolyt-
ic therapy, with the course of treatment
never exceeding 8 weeks owing to the
risk of resistance. The therapy should
therefore not be combined with oral
antibiotic therapy. Marketing authori-
sation has recently been granted in Fin-
land to a combined gel of clindamycin
and benzoyl peroxide which has proven
more effective than either of them
alone, with the problem of resistance
remaining only a minor one (3).
Acne is a long-term inflammatory disease, varying in severity, of the sebaceous glands characterised by clogged
sebaceous ducts, i.e. comedones, papules, pustules and, in the most severe cases, cysts and follicles. They are typically
found on the face, chest and back.
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Very greasy skin with acne should
be treated by daily washing with acid
washing liquids or cleansing emul-
sions, but drying antiseptic washing
agents increase the risk of adverse
effects of topical medical therapies. 
Oral treatments
As an adjunct to topical treatment,
inflammatory acne of moderate severi-
ty also requires internal treatment:
antibiotics, the contraceptive pill or
antiandrogenic therapies. The first
choice antibiotics include tetracycline
hydrochloride 500 mg x 2, lymecycline
300 mg x 1–2, or doxicycline 100 mg
x 1–2. The most cost-effective alterna-
tive is tetracycline. The more recent
derivatives produce a quicker response.
Stomach complaints associated with
erythromycin make its long-term use
difficult. Experience in the use of
azithromycin and roxithromycin for
the treatment of acne is tenuous, with
long-term therapy proving costly. Clin-
damycin should not be used orally in
the treatment of acne due to the risk of
colitis. Trimethoprim is effective in
acne with a daily dose of between 300
mg and 600 mg and should be consid-
ered in the absence of other alter-
natives (4).
The course of treatment with
antibiotics should be restricted to 3–4
months but could be repeated if acne
is not controlled with a topical treat-
ment. Topical treatment should be
borne in mind also during antibiotic
treatment, the logical choice being
benzoyl peroxide, which reduces the
risk of development of resistant bacter-
ial strains. As an adjunct topical
retinoids can also be used. In that case
it is advisable to use benzoyl peroxide
in the morning and retinoid in the
evening in order to avoid their inacti-
vating each other. 
Hormonal therapy is effective espe-
cially in women who also exhibit other
signs of androgen activity: a syndrome
called SAHA (seborrhoea, acne,
hirsutism, androgenetic alopecia). A
combination of cyproterone acetate
and ethinylestradiol has proven to be
the most popular contraceptive pill in
the treatment of acne. The combina-
tion of drospirenone and ethinylestra-
diol appears to be equally effective but
with superior tolerability (5). Instruc-
tions to the patient should include the
mention of the fact that response to
hormonal treatment in acne is not
exhibited until after 6 months of treat-
ment at the earliest. Antibiotic
treatment in the initial stages, and, in
any case, regular topical treatment in
addition to a contraceptive pill, may
be necessary. There is no convincing
proof of reduced effect of a contracep-
tive pill in association with long-term
antibiotic treatment. With the intro-
duction of tighter prescription control
for isotretinoin, female patients of fer-
tile age suffering from moderate or
severe acne should be offered, more
readily than before, an opportunity for
hormonal treatment despite there
being no need for actual contracep-
tion.
Treatment of severe acne
Despite Propionibacteria playing an
aetiologic role in acne there is no ques-
tion of an infection. In severe acne
(nodular, cystic or fulminant form) the
treatment should be focused on subdu-
ing the inflammation. It is consequent-
ly often necessary to initiate the treat-
ment by administering an internal cor-
ticosteroid (prednisolone 0.5–1 mg/kg)
over a 3–6-week period followed by
isotretinoin, an oral retinoid with an
anti-inflammatory effect. In addition
to the reducing effect it has on exces-
sively large sebaceous glands it also
effectively reduces the production of
sebum and consequently also the
quantity of Propionibacteria, and acts
as a comedolytic agent. As a result, it
exerts an effect at every stage of the
pathogenesis of acne, but has no effect
on the quantity of androgen
hormones. It is recommended that
isotretinoin therapy be started with an
initial dose of 0.5 mg/kg and be
increased as necessary according to
response by up to 1 mg/kg to arrive at
a total dose of about 120 mg/kg in the
course of treatment, which usually pro-
duces a long-term response (6). The
adverse reactions resemble those of avi-
taminosis: the unavoidable adverse
effects include dryness of the skin and
mucosa, especially of the lips, whereas
headache and myalgia remain less
common. Transient elevation in the
serum hepatic enzymes and lipid levels
is a possibility and should be checked
after 4–6 weeks of treatment. The con-
comitant use of isotretinoin and tetra-
cyclines should be avoided owing to a
possible increase in the intracranial
pressure. In studies involving large
numbers of patients it has not been
possible to show any increased levels of
risk of depression or suicide, but owing
to idiosyncratic reactions it is recom-
mended that patients with a history of
mood problems be monitored more
carefully than usual (7, 8).  The over-
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whelmingly most important adverse
reaction of the drug is its teratogenici-
ty, and, consequently, contraception
during treatment and for a month
thereafter is absolutely necessary. Half
of pregnancies with onset during treat-
ment are spontaneously aborted, over a
quarter of the children born manifest
visible abnormalities, with an even
greater proportion having internal
abnormalities or retardation in devel-
opment. 
The European Commission’s
stricter prescription control was adopt-
ed in Finland on 1.3.2005. The drug
may still only be prescribed by derma-
tologists, its supply for women of fer-
tile age is restricted to a 30-day course
of treatment on one prescription, and
continuation of treatment requires a
new prescription which is only valid
for seven days. Prescribing by tele-
phone is not authorised. Before the
administration of the drug a pregnancy
test must be carried out in the labora-
tory, which should be repeated as nec-
essary during the treatment and a
month after discontinuation of the
administration. Effective and uninter-
rupted contraception should be started
at least a month before the treatment
and continued for at least a month
after discontinuation of the treatment.
At least two contraceptive measures
should be used, the other one of which
is a mechanical barrier such as a con-
dom. If the doctor finds grounds to
believe that pregnancy is impossible
(e.g. hysterectomy, sterilisation), stan-
dard prescribing practices apply. 
In conclusion
Isotretinoin was already introduced
into clinical use over 20 years ago, and
despite expectations a safer product has
not been introduced since. The drug is
nevertheless extremely effective in the
treatment of severe acne, and despite
uncomfortable adverse effects, motivat-
ed patients very seldom discontinue
the medication. One abortion necessi-
tated by a certain medication is never-
theless one too many, and conditions
introduced to improve the safety are
therefore justified. It is noteworthy
that the doctor still has the possibility
to make an exception from the
prescription conditions if he or she has
grounds to consider it impossible for
the patient to become pregnant. A lit-
tle scope is still left for the exercise of
common sense.
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Indemnity clauses of pharmaceutical
insurance are discussed, with a presenta-
tion of the most common drug groups
involved in injuries and the pharmaceu-
tical injuries that have occurred. 
The number of new compensation
claims for pharmaceutical injury
submitted each year is around 220 on
average, about half of which are success-
ful in their claim. The majority of the
injuries compensated are mild, with
only about 12% of the injured parties
suffering permanent disadvantage.
There has been a slight increase in the
number of pharmaceutical injury claims
since the beginning of the 2000’s, but
the relative proportion of injuries enti-
tling to compensation has remained
fairly stable from year to year. 
A voluntary compensation system
for pharmaceutical injuries has been
operating in Finland since 1984. The
purpose of the insurance is to compen-
sate for the  injury (pharmaceutical
injury) caused by the medicinal prod-
uct, after the product has been released
for consumption in Finland, and the
manufacturer, importer or distributor
has subscribed to the insurance. A phar-
maceutical injury implies a bodily
illness or injury or a comparable severe
mental illness which is likely to have
been induced by the medicinal product
used by the injured party. The insur-
ance will also cover a pharmaceutical
injury occurring in a clinical trial if the
trial has been conducted in accordance
with the regulation issued by the NAM
and the company conducting the trial
has subscribed to the insurance or the
trial is conducted by a principal who
has subscribed to the insurance. In
accordance with Section 3 of the Medi-
cines Act, a medicinal product means a
product intended for human use, blood
administered in a blood transfusion or
blood products, e.g. red blood cells or
thrombocytes, or an intrauterine con-
traceptive device. It is noteworthy that
not all products for sale in Finnish
pharmacies are medicinal products
complying with the Medicines Act, and
not all of them are covered by pharma-
ceutical insurance; this applies for
example to homoeopathic products.
Medicinal products released for
consumption in Finland mean products
that the patients themselves have pur-
chased from a pharmacy, or that they
have received in a hospital or other care
institute or from a doctor’s surgery. An
injury caused by medicinal products
purchased from abroad or via the Inter-
net is not coverable.
Causal relationship
For a pharmaceutical injury to be cover-
able by insurance, certain criteria need
to be fulfilled. It should at first be
determined whether there is a likely
causal relationship between the use of
the product and the injury sustained.
The causal relationship is assessed on
the basis of medical knowledge. The
assessment also relies on supportive data
published in medical publications, and
the register of adverse drug reactions
and compilations prepared on the basis
of these. The most recent data in med-
ical databases is also researched. If the
causal relationship is unknown, the
injury is not coverable as a pharmaceu-
tical injury. The final assessment of the
causal relationship uses a five-stage
scale:
Very likely
The highest possible medical proof
about the causal relationship; the
absence or great unlikelihood of other
possible causes
Likely
The injury has several possible causes,
but given all the other causes as a
whole, the cause in question is the most
likely one
Possible
The injury has several possible causes,
and the cause in question is not more
likely than the rest
Unlikely
The opposite of likely
Very unlikely
The opposite of very likely
Very likely and likely causal relation-
ships fulfil the criteria of an acceptable
pharmaceutical injury. It should also be
borne in mind that the therapeutic
indication of the treatment and its
management need to be appropriate for
the criteria of approval to be fulfilled.
The coverability of pharmaceutical
insurance is also influenced by the
degree of severity. An injury may be
considered coverable if it has caused a
minimum of 14 days of continuous dis-
ability or reduced functional ability,
permanent illness, bodily injury or
death. If the injury remains a minor
one, there is no compensation for pain
or ache, but the costs and loss of
income will be compensated should
they exceed the limit of minor injury,
which is 85 Euro at present in Finland. 
It should then be determined
whether the injury is a result of
unavoidable risk having been taken dur-
ing treatment of a severe illness or
injury, or whether, given the quality and
severity of the illness treated, and given
the severity of the injury caused by the
medicinal product and the likelihood of
occurrence of the injury, for example,
the injury should, within reason, be
considered a tolerable one. A pharma-
ceutical injury occurring under these
conditions will not be compensated for.
An example of unavoidable risk-taking
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An injury covered by pharmaceutical insurance
is where a cancer patient with a poor
prognosis contracts agranulocytosis and
polynephropathy as a result of cytostatic
therapy. Here there is no question of a
coverable pharmaceutical injury. An
example of an injury which ought with-
in reason to be tolerated and will not be
compensated would be weight gain
caused by an antipsychotic agent. Ineffi-
cacy of a medicinal product is not a
pharmaceutical injury. But if the
patient’s medication or other treatment
prescribed has been managed inade-
quately, or if an error has occurred in
the supply of the medicinal product by
the pharmacy, compensation for the
injury sustained may be applied for
from the patient insurance. These, how-
ever, are not pharmaceutical injuries. 
Pharmaceutical insurance is
secondary in comparison with other
statutory insurances, and any receivables
or payable benefits from statutory
insurances or other public funds will
therefore be deducted from it prior to
payment. The claims procedure follows
the standards of the Claims Board for
Traffic Accidents. For the assessment of
permanent disadvantage accrued, the
Ministry of Social Affairs and Health
classification of handicaps is applied.
The doctor in charge of the
treatment gives his or her own descrip-
tion of the injury by using a separate
form. It is desirable that the doctor
describes the patient’s ability to func-
tion, especially following injury, and
does it in as close detail as possible. It
will be easier for the advisory medical
officer to form an opinion of the severi-
ty of the injury and the degree of pain
and discomfort the patient has suffered,
not to speak of permanent disadvan-
tage, if, for example, following damage
of the Achilles tendon, a description is
given of the patient’s ability to move,
the analgesics that were needed, the
duration of medication, and the length
of time that the patient has been on
sick leave and normal ability to
function has been restricted. If, instead,
the doctor’s certificate only states: par-
tial rupture of the Achilles tendon detected
by ultrasound, no conclusions of the
kind mentioned above can be drawn
and additional reports will be required,
and this unavoidably delays the out-
come of the proceedings.
Compensation from the Pharma-
ceutical Insurance Pool should be
applied for within three years from the
moment when the patient was made
aware of the injury caused by a medici-
nal product, and within ten years at the
latest from the time when the adminis-
tration of the product was disconti-
nued. Every report of an injury is dis-
cussed in a group of experts from the
Insurance Pool, the members of which
include a chief medical advisor, a claims
manager, claims lawyers and claims
clerks. Compensation criteria are avail-
able at the website of the Pharmaceuti-
cal Insurance Pool (www.lvp.fi).
The number of the injuries
compensated and the most
common injuries
In the past five years the number of
reports of new pharmaceutical injuries
has varied between 162 and 280 a year.
Of these, 51–61% resulted in compen-
sation. This number has remained fairly
constant since the first days of existence
of the insurance.
The highest number of pharmaceu-
tical injuries are caused by the medici-
nal products most used. Consequently,
in 2001–2005, anti-infectives for
systemic use (ATC Code J) caused the
highest number of coverable injuries, a
fifth of all. Drugs acting on the nervous
system (ATC Code N) caused 9% of
the injuries compensated, quinolone
antibacterials (ATC Code J01M) 7%,
anti-inflammatory analgesics and anti-
rheumatics (ATC Code M01A) 5% and
hormonal contraceptives for systemic
use (ATC Code G03A) 4% of the
injuries.
The most common pharmaceutical
injuries included adverse skin reactions
(ca. 10% of all injuries). Some of these
consisted of severe skin and mucous
membrane damage (mucocutaneous
syndrome or epidermal necrolysis),
which also frequently led to permanent
adverse cosmetic effects. Tendon
injuries caused by quinolone antibacte-
rials accounted for 6%, as did liver
effects and nervous system effects (e.g.
polyradiculitis).
Over 60% of the injuries were mild,
resulting in a maximum of one week’s
hospitalisation or two months’ incapaci-
ty for work or a reduction in functional
ability. Furthermore, the patients recov-
ered fully in more than 80% of the
cases, which further supports the inter-
pretation of the injuries as mild. An
injury left about 12% of the patients
with a permanent adverse effect. Over a
period of 20 years, 59 patients have suc-
cumbed to a pharmaceutical injury.
This means less than 3 deaths a year.
The most common pharmaceutical
injuries resulting in death included pul-
monary fibrosis, pulmonary or cerebral
embolism, liver damage, serious epider-
molysis or bone marrow damage.
Why have the injuries been
rejected?
The most common reason, accounting
for 45% of the rejections, was the
absence of a causal relationship between
the medicinal product and the injury
sustained. A fifth of the cases involved
an injury which was tolerable within
reason or associated with unavoidable
risk-taking, and in 15% of the cases the
injury remained minor. There were sel-
dom any other criteria for rejection
involved.
In conclusion
The pharmaceutical insurance system
which has operated in Finland since
1984 guarantees an equal opportunity
for all patients to secure compensation
for unexpected injury caused by a medi-
cinal product. Both the number of
reports of pharmaceutical injury and
the number of claims approved have
remained fairly unchanged from year to
year, even though the number of new
reports has somewhat increased since
the beginning of the 2000’s. About half
the reports result in compensation.
Since the most important criterion for
rejection is the absence of a causal rela-
tionship between the product and the
injury sustained, a careful consideration
of the causal relationship and the com-
pensation criteria would be beneficial to
the claimant. It is noteworthy, however,
that the number of injuries compensat-
ed is totally different from what is from
time to time publicly suggested.
Furthermore, unlike what is publicly
suggested, the majority of the injuries
reported have been mild. It may also be
possible that some of the incidents
caused by medicines – including the
more severe ones – remain unreported
to the Pharmaceutical Insurance Pool. It
is therefore recommended that doctors
keep the possibility of a pharmaceutical
injury in mind and advise their patients
about the insurance available.
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It is 40 years ago this year since the
National Board of Health in Finland,
in the aftermath of the thalidomide
catastrophe, started collecting reports
of adverse drug reactions (ADRs) into
its register. Last year the adverse drug
reaction register of the National
Agency for Medicines crossed the bor-
derline of 20,000 reports in total, and
a new annual record was also reached,
with 1,224 reports received. Of these,
657 (54%) were of  serious reactions.
ADR reports are received from
doctors, dentists and pharmacists.
Marketing authorisation holders also
report serious ADRs of which they
become aware. Adverse reactions asso-
ciated with intervention studies are not
reported to the ADR register. This
article deals only with reports called
spontaneous, i.e. adverse reactions
published in the literature are not dealt
with. Adverse reactions caused by vac-
cinations (92 reports) are also omitted.
The ADR report which can be
filled in and forwarded on the Internet
has had a good reception. Last year
150 of the reports sent by healthcare
professionals were in electronic form.
The proportion of electronically sub-
mitted reports increased from 3% in
March to 36% in November, the pro-
portion in December being 22%. The
electronic report form is available at
http://hava.nam.fi. For submitting a
report, a FiMnet identification code is
required. A conventional report form
which can be printed out is also avail-
able at www.nam.fi.
All ADR reports submitted to
NAM are evaluated on a weekly basis
at the meeting of experts of the Safety
and Drug Information Department.
The need for any follow-up measures
is judged at the same time. The details
submitted are occasionally inadequate
for making an assessment, which ren-
ders it necessary to contact the person
submitting the report for further
details. 
In 2005 the number of medicinal
substances reported on was 333, but
on the majority of these only a couple
of reports were received. The table lists
the medicinal substances which were
reported on 10 or more times (a total
of 32 substances). The list contains
several ‘constant favourites’ with the
anti-psychotic clozapine, for example,
having figured in the 1st to 4th posi-
tion on the list of most frequently
reported drugs for the last 10 years,
while the number of reports received
annually has varied between 21 and
44. As before, the majority of the
reports on clozapine (25) this year
concerned leucocyte reactions of vary-
ing degrees of severity.
On reviewing the list it should be
borne in mind that safety of the medi-
cinal substances cannot be compared
with one another on the basis of the
number of reports submitted. There is
a significant variation in the number of
users, and drugs in frequent use may
be more frequently reported on than
those less frequently used. The adverse
reactions caused by more recent drugs
are probably reported more often than
those caused by old and well-known
drugs. It may also be that adverse drug
reactions which hit the headlines
increase the reporting on that specific
drug.
Pregabalin and anti-epileptics
Pregabalin (marketing authorisation
grated in 2004), is a GABA analogue
used in adults for peripheral pain and
as an adjunct for partial epileptic
seizures. 
The ADR reports on pregabalin
totalled 41. Half of the patients (20) in
these reports were over 65 years of age.
Only one used pregabalin for epilepsy;
the rest used it for (neuropathic) pain.
The daily doses at the onset of adverse
reaction varied between 25 mg and
300 mg, and about half of the patients
were taking a daily dose of 150 mg.
On review of the reactions consid-
ered the most important ones in each
report on pregabalin, the nervous sys-
tem (18 in total) outnumbered the
rest. The reactions reported included a
reduced level of consciousness (3
reports), muscular cramps (2), vertigo
(2), confusion (2), somnolence (2),
tremor, memory disturbances, seizures,
transient hemiparesis, restlessness,
walking difficulties and visual halluci-
nations. Many of these are well-known
reactions listed in the SPC. Exacerba-
tion of cardiac failure, elevation of
hepatic enzymes and nausea were each
reported twice, while the remainder
were isolated single reports.
According to the SPC, in both
therapeutic indications the treatment
can be initiated with a daily dose of
150 mg, and the dose may be
increased gradually up to a maximum
daily dose of 600 mg depending on
the response and tolerance of the
patient. The dose should be adjusted
according to creatinine clearance if the
patient’s renal function is impaired. It
may be necessary to reduce the dose
for the elderly for the same reason, and
caution is recommended at the start of
the treatment with, for example, a sug-
gested initial dose of 25 mg twice
daily. 
Adverse Drug Reaction register 2005 – some
new, some old
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The antiepileptic drugs next most fre-
quently reported were lamotrigine (12)
and valproic acid (10). As anticipated,
the most commonly reported adverse
reaction caused by lamotrigine was
rash (5 reports); among the reactions
caused by valproic acid pancreatitis was
reported twice, as was granulocytope-
nia, and the rest of the adverse
reactions were each reported once only. 
Antipsychotics, antidepres-
sants and bupropion
In addition to clozapine, the list of the
most frequently reported antipsycho-
tics included quetiapine (22 reports)
and risperidone (17 reports). The most
commonly reported reactions caused
by quetiapine included elevated hepat-
ic enzymes (4 reports), and granulocy-
topenia, tachycardia and malignant
neuroleptic syndrome, each of which
was reported twice. The use of risperi-
done was also reported to have been
associated with 2 cases of malignant
neuroleptic syndrome, and hyperpro-
lactinaemia, elevation of hepatic
enzymes and rash were reported twice
each. Malignant neuroleptic syndrome
has also been reported in association
with the use of atypical neuroleptics,
albeit rarely (Poutanen and Kiviniemi,
2004).
The most commonly reported anti-
depressants included mirtazapine (17
reports) and venlafaxine (12). Mirtaza-
pine was reported to have caused the
following reactions twice or more fre-
quently: leucopenia of various degrees
of severity (3 reports), seizures (2) and
restless legs (2), and weight gain (2).
All of these are known adverse
reactions of mirtazapine. The most fre-
quently reported reactions caused by
venlafaxin were withdrawal symptoms
(4 reports), and skin symptoms (3).
One report was received on fatal sero-
tonin syndrome associated with an
overdose of venlafaxin.
Bupropion (a non-nicotine aid)
was reported on 13 times, on eight of
which various skin symptoms (urti-
caria, rash, folliculitis) were described.
Three reports described various
nervous system reactions (somnolence,
confusion, hypoaesthesia, restlessness,
vertigo).
Contraceptives
Levonorgestrel with its 25 reports
reached the 3rd place in the most fre-
quently reported drugs list. One of the
reports was on minipills and the rest
on Mirena, a hormonal IUD. There
were 10 cases of unintended pregnan-
cies reported in association with Mire-
na, four of which were ectopic. The
Pearl index of hormonal IUDs (num-
ber of pregnancies per 100 woman
years) is 0.1 and copper IUDs 0.6.
The risk of ectopic pregnancy without
contraception is estimated at 1:100, in
women using a copper IUD the risk is
1:1,000 and a hormonal IUD 1:5,000
(Heikinheimo and Lähteenmäki,
2004). It is possible that a pregnancy
(ectopic) in women using a hormonal
IUD is so unexpected that the thresh-
old for reporting is exceeded. Other
adverse reactions caused by Mirena are
menstrual bleeding disturbances and
skin symptoms (2 reports of each), the
rest of the reactions being isolated.
NuvaRing (etonogestrel and
etinylestradiol), the contraceptive vagi-
nal ring, was reported on in 21 reports
in total, 15 of which were about unin-
tended pregnancies. Thromboembolyt-
ic incidents were referred to in two
reports, as were topical symptoms (cer-
vicitis, vaginal irritation).
Evra contraceptive patch (norelge-
stromine and ethinylestradiol) was
named in 11 reports, 10 of which
related to unintended pregnancy and
one to deep vein thrombosis. Accord-
ing to the SPC, weight may be an
attributable factor for a reduction in
contraceptive efficacy in individuals
weighing over 90 kg. The weight of
the woman who became pregnant was
mentioned in only three instances.
There were 10 reports received on
Yasmin contraceptive pill, which con-
tains drospirenone and ethinylestradi-
ol. Six of these concerned unintended
pregnancies (one a case of blighted
ovum pregnancy), three thromboem-
bolic incidents (two of pulmonary
embolism) and one a case of elevation
of hepatic enzymes.
According to the SPC, studies on
NuvaRing demonstrated a Pearl index
of 0.4–1.3 in correct use and 0.6–1.7
when incorrect use is also accounted
for. The SPC for Evra states Pearl
indices of 0.7 and 0.9, respectively. It
is possible that the proportion of
incorrect use outside any studies is
even higher.
The estimated Pearl index of com-
bination contraceptive tablets, when
used correctly, is 0.1 and, in typical
use, 3 (Heikinheimo and Lähteenmäki,
2004). Forgetting to take the tablet is
fairly common, and consequently, the
contraceptive efficacy will naturally be
reduced. Reports on failed contracep-
tion are generally fairly inadequate and
do not allow a conclusion to be drawn
as to whether the use has been appro-
priate or not. It may often be the case
that the person who submits the report
does not know this either.
Antimicrobials
A total of 25 reports on levofloxacin
were received in 2005, nineteen of
which related to the Achilles tendon:
tendinitis (9) and rupture of the
Achilles tendon (10), which are well
known in association with the use of
In English
The medicinal substances most
frequently reported on in 2005
pregabalin 41
clozapine 35
levonorgestrel 25
levofloxacin 25
tamsulosin 24
etoricoxib 22
quetiapine 22
etonogestrel + ethinylestradiol 21
atorvastatin 18
mirtazapin 17
terbinafin 17
zoledronic acid 17
risperidone 17
valdecoxib 16
rosuvastatin 15
infliximab 15
simvastatin 14
bevasizumab 14
capecitabine 13
bupropion 13
insulin glargine 12
ezetimibe 12
isotretinoin 12
etanercept 12
lamotrigine 12
venlafaxine 12
iomeprol 12
norelgestromin + ethinylestradiol 11
ciprofloxacin 11
drospirenone + ethinylestradiol 10
adalimumab 10
valproic acid 10
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fluoroquinolones (Pohjola-Sintonen
and Kannisto, 2004). The adverse drug
reaction reports on fluoroquinolones
totalled 42, of which 26 concerned the
Achilles tendon. Damage of the plan-
tar fasciae and a tendon of a digit were
reported once each. The rest of the
reactions were isolated cases.
Terbinafine was reported on 17
times in 2005, i.e. an unchanged level
of reporting compared with the previ-
ous year (15). Also similarly to the pre-
vious year, the reaction most frequent-
ly reported on was the well-known one
of loss of taste or taste disturbance (7
reports), with various rashes coming in
second place (6 reports). Elevation of
hepatic enzymes was reported twice
and pancreatitis once.
Tamsulosin
Of the 24 reports received on tamsu-
losin, 21 described intraoperative flop-
py iris syndrome. The CHMP’s Phar-
macovigilance Working Party evaluated
this adverse reaction under the leader-
ship of Finland, and the SPCs are at
present updated with appropriate
warnings inserted in them.
Coxibs 
A total of 48 reports were received on
coxibs last year; 22 of them concerned
etoricoxib, 16 valdecoxib (the market-
ing authorisation of which is suspend-
ed), 8 selecoxib and 2 rofecoxib, with-
drawn from the market in autumn
2004.
Of the adverse reactions associated
with etoricoxib, 8 concerned various
hypersensitivity reactions (such as rash-
es and mucous membrane symptoms,
including one anaphylactic reaction), 7
on the cardiovascular system (one car-
diac and one cerebral infarction), and
the rest were various isolated reactions.
The reports on valdecoxib associated
with the cardiovascular system totalled
6 (one cerebral infarction), various der-
matological symptoms 5, and liver
reactions 2. Among the reports
received on celecoxib, facial and oral
oedema was mentioned three times
and urticaria twice, with the rest of the
reactions being isolated (e.g. hepatitis
and pancreatitis).
Statins and ezetimibe
The reports on statins in 2005 totalled
53. The majority of them were on
atorvastatin (18 reports), followed by
rosuvastatin (15) and simvastatin (14).
The majority (29) of all the reports on
statins concerned muscular reactions of
varied severity (mostly myalgia and/or
elevation of creatine kinase levels), fol-
lowed by liver reactions (10). These are
very well known adverse reactions
related to statins.
Ezetimibe, introduced on to the
market in 2003, emerged for the first
time on the list of drugs most
frequently reported. A total of 12
reports were received, two of which
described myalgia and mildly elevated
creatine phosphokinase levels  in
patients with earlier similar symptoms
caused by statins. The rest of the
reports concerned various reactions,
three of which involved the digestive
organs and three the skin.
Zoledronic acid
There were 22 reports received on bis-
phosphonates, the majority of which
were concerning zoledronic acid (17
reports). Both zoledronic acid and its
adverse reaction most frequently
reported, osteonecrosis of the jaw (8
reports), were novelties on the list of
reactions most frequently reported.
Multiple myeloma was the cause of the
treatment in seven of these patients,
and advanced cancer in one patient.
Osteonecrosis of the jaw is des-
cribed in the SPC. The majority of the
cases were related to dental treatment,
often including infection. Before intro-
ducing treatment with bisphos-
phonates, dental examination and pro-
phylactic dental treatment should be
considered, while avoiding invasive
dental procedures as far as possible
during the treatment. 
The Pharmacovigilance Working
Party has prepared a class review of bis-
phosphonates related to osteonecrosis
of the jaw. Even though this reaction is
especially associated with parenteral
bis-phosphonates indicated in cancer
treatment, the SPCs for oral bisphos-
phonates will also be updated.
Immunosuppressive agents
Infliximab was reported on 15 times in
2005, etanercept 12 times and adali-
mumab 10 times. Infections attribut-
able to tuberculosis accounted for
seven of these. A total of 18 reports of
tuberculosis infection related to the use
of immunosuppressive agents (ATC
Code L04AA) were received by the
adverse drug reaction register.
Hepatic reactions attributable to
infliximab were reported 5 times (one
of them being hepatocellular carcino-
ma) and reactions of hypersensitivity 4
times (one anaphylactic reaction),
while tuberculosis infections numbered
3. Two reports of sepsis were received
involving etanercept, and these also
included bacterial arthritis, while one
report concerned tuberculosis
infection, one malignancy (ovarian car-
cinoma) and one an allergic reaction.
Tuberculosis infection was the most
frequently reported adverse reaction to
adalimumab (3 reports; and one case
of Mycobacterium avium infection),
while cerebrovascular disorder was
reported twice, oedema also twice and
malignancy once (breast cancer).
In English
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Antineoplastic agents
A total of 53 reports were received on
antineoplastic agents (ATC Code L01).
The most frequently reported ones
were bevacizumab (14 reports), an
angiogenesis inhibitor indicated for the
treatment of colorectal cancer, and oral
capecitabine (13 reports), a precursor
of 5-fluorouracil.
Five of the reports on bevacizumab
concerned thromboembolic reactions
(3 cases of pulmonary embolism and 2
of venous thrombosis), 3 concerned
haemorrhagic complications (epistaxis,
melaena and cerebral haemorrhage),
while cardiovascular reactions were
reported on three times, and intestinal
perforation twice.
Four of the reports of adverse reac-
tions attributable to capecitabine were
about cardiac reactions, three of which
described chest pain. There were
reports of granulocytopenia. The rest
of the reports were on isolated adverse
reactions.
Insulins
Long-acting insulins were reported on
20 occasions. Insulin glargine (12
reports) is a newcomer to the list of
the most frequently reported adverse
reactions. The majority of the cases
were of high blood sugar values (4
reports), three of them reporting a
malfunctioning dosing device, and one
efficacy problems with the drug. Drug
interactions leading to changes in the
blood sugar values were reported three
times (the suspected  interacting drugs
were eye drops of brimonidine and
betaxolol, enalapril and tramadol).
Insulin detemir was reported on 8
times, on most occasions in
connection with hypoglycaemia (5)
and injection site reactions (2).
Isotretinoin
A total of 12 reports were received of
adverse reactions to isotretinoin, which
was also a new introduction to the list
of the most frequently reported drugs.
Deep vein thrombosis was reported
twice, and so were elevation of liver
values and myalgia or arthralgia. One
report described the suicidal thoughts
and withdrawal from school work of a
17-year-old adolescent. The connect-
ion between isotretinoin and suicide
has come under a lot of discussion. 
Contrast media 
Iodine-containing contrast media are
also ‘constant favourites’. A total of 45
reports were received, iomeprol being
the individual agent mostly reported
(12 reports). Almost without
exception, the reports on contrast
media concerned reactions of hyper-
sensitivity, such as urticaria and
mucous membrane symptoms.
Anaphylactic shock was described in
two reports.
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Report of adverse drug
reaction 
It is recommended that a report
be sent to the NAMs ADR
register about all adverse reac-
tions established and suspected,
especially when the reaction is
serious, an adverse interaction
between two drugs is suspected,
an unexpected adverse reaction
occurs (the reaction is not men-
tioned in the SPC), the reaction
is attributable to a new drug
introduced on to the market less
than 2 years ago, or when the
frequency of the reaction appears
to be increasing according to the
person who submits the report.
The reactions are considered
serious when they have
•  resulted in death
•  been life-threatening
•  caused/prolonged hospitalisa-
tion
•   caused disabling/incapacitat-
ing, or
•  caused congenital
anomaly/birth defect
In English
TABU 2.2006 66
During the past decade the National
Agency for Medicines in Finland has
commissioned several studies on the
natural rubber allergen contents of
latex gloves. The studies have shown
that the average allergen contents in
the gloves have continuously
decreased, except for the past two
years. It would appear, however, on the
basis of a study conducted in 2005 on
the gloves available on the market at
the time, that this favourable develop-
ment has come to a halt, while the dif-
ferences in the allergen contents are
not great. The situation can still be
considered good, as 26% of the 84 dif-
ferent types of latex gloves manufact-
ured by 20 companies showed no aller-
gens, and 46% showed only a small
allergen content.
In general
Surgical and examination gloves manu-
factured of latex, i.e. natural rubber,
have long been known to cause allergic
reactions in their users. The first reac-
tions were detected as early as 1979.
The symptoms include, for instance,
topical or generalised urticaria, pruri-
tus, excema of the hands, conjunctivi-
tis, rhinitis, asthma, and even anaphy-
lactic shock. The risk groups include
extensive users of gloves such as health-
care professionals, especially doctors
and operating theatre staff, dentists
and dental nurses, users of household
and protective gloves, small children
with food allergy, atopic individuals,
individuals suffering from dermatitis of
the hand, and, for example, patients
with spina bifida. Sensitisation to nat-
ural rubber is diagnosed with the aid
of a skin prick test or by demonstrat-
ing latex specific IgE-class antibodies
in the serum. The presence of allergy is
established either by explicit symptoms
or by a glove exposure test. During the
past two decades, the use of protective
gloves has become common as a result
of the risk of infectious diseases. Their
use has consequently increased the
number of individuals sensitised to
latex. Studies show that less than 1%
of the general population and 3–10%
of healthcare professionals in Finland
are suffering from latex allergy. 
When natural rubber allergy
(immediate type I reaction to proteins
in the rubber tree latex) was diagnosed
in glove users and patients, the manu-
facturers and authorities took measures
to reduce the allergen content in the
latex products used in health care. The
NAM started to monitor the allergen
contents of latex gloves on the market
in Finland in 1994. The studies were
conducted in collaboration with the
National Public Health Institute, Lab-
oratory of Immunology, and Tampere
University Hospital, Department of
Dermatology. The responsible
researchers in the studies were Timo
Palosuo, Professor Emeritus, and Kris-
tiina Turjanmaa, Senior Lecturer,
Department of Dermatology, Tampere
University Hospital.
A commercial quantitative test
method (FITkitTM) has been developed
in Finland for the accurate measure-
ment of allergen content. A compari-
son of this test and conventional IgE-
based methods has shown a highly sig-
nificant correlation between the total
glove extract allergenicity, skin prick
test reactivity and the sum of four clin-
ically important latex allergens (Hev
b1, Hev b3, Hev b5 and Hev b6.02).
This commercial test method was used
in the study carried out in 2005. In
the test, the allergens dissolved from
the glove extracts are captured on to
the ELISA plates by monoclonal anti-
bodies. Allergens are determined by
specific enzyme-conjugated monoclon-
al antibodies which react against other
structures (epitopes) in the allergen
molecules. The standard method used
in the six studies conducted previously
was the latex IgE-ELISA-inhibition
technique. Its use in the present mar-
ket studies has been discontinued
because of the inadequate availability
of the type of serum mixture from sev-
eral latex allergenic individuals in
which the required spectrum of IgE-
class latex allergen antibodies would be
found.
Requirements regarding
gloves, and for introducing 
on the market
Requirements with regard to the safety
and suitability for the purpose of surgi-
cal and examination gloves intended
for introduction into use and on to the
market were enforced in 1995, at the
same time as the Finnish legislation on
medical devices was harmonised with
the European Directive. Consequently,
manufacturers operating in third coun-
tries should comply with the same
requirements regarding safety and suit-
ability. Latex glove manufacturing
units are in fact mainly found in Thai-
land, Indonesia and Malaysia, where
the producers of the raw material, rub-
ber, are also located.
Compatibility between latex and
the tissues, cells and fluids of the body
remains a challenge. Extraction of the
protein content from the raw material
of the glove is problematical, as it is
impossible to manufacture latex gloves
without the use of natural rubber pro-
teins. However, it is possible to reduce
the allergy-inducing protein content
significantly by making the methods
used during manufacture more effec-
tive. The harmful components of the
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protein content have been identified,
and two of them have been demon-
strated as the most important key aller-
gens in natural rubber (Hev b5 and
Hev b6.02). Another two allergens
(Hev b1, Hev b3) studied with the
help of FITkit are significant for
patients with spina bifida.
Gloves are required to have good
chemical, physical and biological prop-
erties. Gloves manufactured from nat-
ural rubber have good protective prop-
erties, durability and flexibility, and,
consequently, despite the risk of aller-
gy, natural rubber remains the most
important material for gloves. 
The manufacturer should carry out
a risk analysis on the gloves, in which
the benefits of use should be weighed
against the risks. In addition to tissue
compatibility, the appropriateness of
the agents that come into contact with
the gloves and their effect on the mate-
rial of the gloves should also be
assessed.
Lowering of the allergy-inducing
protein contents of the gloves takes
place at various stages of the manufac-
turing process. The methods by which
the allergen content has been reduced,
or allergens removed, should be dem-
onstrated and documented by the
manufacturer.
There are no commonly accepted
limit values for allowable allergen con-
tents stipulated by the EU. The Euro-
pean Commission Scientific Commit-
tee states that the amount of allergens
should be made as low as reasonably
possible. The methods generally used
by manufacturers to measure the
amount of soluble proteins only mea-
sure the total amounts of protein, not
allergising proteins alone, and there-
fore cannot be used in the determina-
tion of a safe level of allergen content. 
In practice, however, the risk can-
not be removed entirely. Therefore, the
package labelling should give the con-
sumer information about the safe use
and appropriate storage of the gloves.
An EU Commission guide for manu-
facturers and for notified bodies con-
ducting compliance assessments con-
tains practical advice for risk assess-
ment. It contains guidelines for the
management of the manufacturing
process and package labelling. It is rec-
ommended in the guide that packages
of latex containing products should
clearly indicate that the product con-
tains latex, i.e. natural rubber, and that
the product may cause an anaphylactic
reaction in individuals allergic to latex.
Terms such as relatively safe, minimal
allergenicity, hypoallergenic or low pro-
tein content should not be used because
they give an unjustifiable impression of
the amount of allergens. The labelling
should reveal whether the gloves are
prepowdered or powder-free. The
packages of prepowdered surgical and
examination gloves should include
advice to minimise tissue exposure
induced by residual powder.
The specific details required to be
given about sterile gloves include the
date of manufacture, expiry date and
method of sterilisation. The packages
should include an indicator showing
the sterilisation carried out.
It is required in Finland that pack-
age labelling should include the infor-
mation necessary for safe use both in
Finnish and Swedish, whereas the rest
of the information can be given in
English. In the rest of the information
given the manufacturers generally pre-
fer to use the symbols set out in stan-
dard EN-980.
Results of the glove study
2005
In the glove study commissioned by
the NAM in 2005 the allergen levels
are classified in five categories. The
new classification is based on compar-
isons with the previous methods. The
values of FITkit are given as the total
amount of four glove allergens in
weight units per one gramme of glove.
The levels are as follows
✦ Very low allergen content (non-
measurable, i.e. the total of four
allergens is below 0.03 µg/g)
✦ Low allergen content (0.03–0.14
µg/g)
✦ Borderline allergen content
(0.15–0.29 µg/g)
✦ Moderate allergen content
(0.30–1.14 µg/g)
✦ High allergen content (≥ 1.15
µg/g)
Of the 84 glove types studied 39
were placed in categories ‘very low’ and
‘low’. Of these, 22 gloves had no mea-
surable amounts of allergens. Nearly
half of the gloves on the market were
included in the low allergen category.
The borderline contained 7 gloves and
moderate contents were found in 25
gloves. However, there were still 13
types of gloves which exceeded the
high content level. Gloves that have
moderately elevated or high contents
cannot be recommended for use
because of the significant health risk
associated with their use.
Even though the study involved a
specific batch produced by each manu-
facturer, it nevertheless shows that
some manufacturers already in their
production apply methods to reduce
the allergen contents. It can be
assumed that the markets are offering
an adequate number of the type of
gloves in which the natural rubber
allergen content is low to such a degree
that they are appropriate for most sen-
sitised and, unknown to themselves,
allergic individuals (very low, low).
The safest alternative for individuals
with diagnosed latex allergy are gloves
free of natural rubber and with ‘very
low’ allergen content, of which there
are also several types available on the
market. Totally latex-free gloves are
necessary in healthcare in the treat-
ment of patients with natural rubber
allergy.
Nearly all glove packages are
marked that the product contains latex
and serve as a warning that latex can
cause allergic reactions. This inform-
ation will guide the latex-sensitised
consumer to choose gloves which are
totally latex-free. With only a couple
of exceptions, the packages of gloves
included the required information. 
The language requirements in the
package labelling information were
inadequately fulfilled. The chances of
influencing manufacturers in third
countries to correct the language in
their package labelling are minimal.
Stringent national language require-
ments may lead to otherwise good
products being dropped out of the
market because of the reluctance of the
manufacturer to make amendments for
a small market area. 
Continuous improvement of
quality
Allergen content studies on latex gloves
have been conducted in Finland since
In English
1994. Each study has always involved
a specific batch of the gloves the man-
ufacturer has had on the market at that
particular time. The purpose of the
studies has been to monitor the
changes taking place in the allergen
contents of the manufacturer’s gloves
when the risk of allergy has been
focused on in international studies and
study results on allergen contents have
been published. The choice of glove
plays an important role in the preven-
tion of an increase in latex allergy.
The invitations to tender process
ought as a rule include a request that
test results of any batch ordered from
the manufacturer should indicate the
allergen content in the batch.
Comparisons of production quality
between manufacturers are difficult
with regard to the batch specific study
results since the trade names of gloves
are frequently changing. Whenever it
has been possible, however, uneven
product quality of one and the same
manufacturer has been detected, and it
is therefore not possible to draw any
conclusions about reliable manufactur-
ers. There has nevertheless been quite a
big improvement in the situation in
the past ten years.
There should be several ways of
proceeding with the lowering of the
latex gloves’ allergen contents, some of
which would be the development of
standards and quality requirements,
collaboration between the regulatory
authorities in market control, and
monitoring of glove production and
research.
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In English
Translation Mervi Moisander
NAM reviewed the quality of drug information
received by patients
NAM has published a summary of the research carried out into drug information and its quality. The results compiled
appear in a review in English, Drug information for consumers and patients - a review of the research. The intention is to
contribute to the discussion and development concerning drug information both in Finland and on the EU level. The
important themes include the sources, methods of distribution, special needs and future challenges of drug information.
The volume of information that patients need about their medication in order to participate in and influence the decision
making about their own treatment has increased. The most common sources of drug information are the doctor and the
pharmacy personnel. Patients are also looking for information in the package leaflets, on the Internet and in newspapers and
magazines. The drug information available varies in quality, however. Good information is often difficult to distinguish from
bad.
The review maintains that patients and consumers should be given tools and guidelines for assessing drug information. It
should be easy to identify the origin, source and possibly even the financier. Improving the quality and availability of drug
information is one of the targets set by the European Union. The European Medicines Agency (EMEA) is constructing a
gateway through which reliable and evaluated information about drugs would be delivered to healthcare professionals and
patients. In addition, the importance of the national pharmaceutical regulatory authorities in producing and delivering reli-
able information about drugs would be likely to increase.
The publication may be obtained from http://www.nam.fi/english/publications/
Ulla Närhi
The publication may be obtained from http://www.nam.fi/english/publications/
